Skip to main content

Kurma Partners — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

84
Companies
$1.8B
Total invested
$26.0M
Avg. check
25
Industries
Health Care 16Biotechnology 14Medical 8Pharmaceutical 8Therapeutics 5Life Science 4+19 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 4972 of 84
Nuclidium
July 2025

Nuclidium is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics.

Health Care · Basel$99.2M Series B
Minoryx Therapeutics
July 2025

Minoryx Therapeutics offers pharmacological chaperones, which are small molecule drugs used for the treatment of genetic diseases.

Biotechnology · Barcelona$31.5M Grant
EvlaBio
July 2025

EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs.

Biotechnology · Zürich$24.6M Seed
Elkedonia
June 2025

Elkedonia is a biotech company dedicated to transforming antidepressant therapy.

Biotechnology · Strasbourg$12.9M Seed
Nuevocor
May 2025

Nuevocor operates as a preclinical-stage biotech company.

Biopharma · Singapore$45.0M Series B
Avidicure
April 2025

Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality.

Oegstgeest$50.0M Seed
Brink Therapeutics
April 2025

Brink Therapeutics is a Biotechnology Research firm conducting cell therapy research using reprogrammed recombinases.

Biotechnology · Paris$4.0M Seed
Hopia
January 2025

Optimized resource planning solution for healthcare institutions

Health Care · Paris$3.6M Seed
Coave Therapeutics
January 2025

Horama develops gene therapies for rare inherited ocular and CNS (central nervous system) diseases.

Biotechnology · Paris$32.9M Series A
Omnidoc
December 2024

Omnidoc is a tele-expertise platform for healthcare professionals to exchange medical opinions.

Collaboration · Paris$6.3M Series Unknown
Meiogenix
December 2024

Meiogenix is a biotechnology company that develops breeding technologies.

Biotechnology · ParisSeries A
Raidium
November 2024

Radiology augmented GPT to tackle the complexity of precision medicine

Artificial Intelligence (AI) · Paris$16.9M Seed
PanTera
September 2024

PanTera produces actinium-225 for personalized cancer treatment and radiopharmaceuticals.

Health Care · Mol$110.3M Series A
ImCheck Therapeutics
August 2024

ImCheck Therapeutics designs and develops immunotherapeutic antibodies for the treatment of cancer and autoimmune disease.

Biopharma · Marseille$22.4M Grant
Spotlight Medical
July 2024

Spotlight Medical develops AI tests to revolutionize cancer treatment, providing everyone with the best possible chance to beat cancer.

Artificial Intelligence (AI) · Paris$6.8M Seed
SciRhom
July 2024

SciRhom is a biotech enterprise that translate advanced scientific findings into game-changing therapies for autoimmune diseases.

Biotechnology · Martinsried$68.1M Series A
Vico Therapeutics
June 2024

Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.

Health Care · Leiden$12.3M Series B
Tacalyx
June 2024

Tacalyx is a biotech company focused on the discovery and development of novel anti-TACA

Biotechnology · Berlin$7.5M Seed
FeetMe
June 2024

FeetMe is a digital health company that provides a technology platform for in-clinic and real-world gait and activity assessments.

Fitness · ParisSeries B
Safe Orthopaedics
March 2024

Safe Orthopaedics is a France-based company principally engaged in the medical devices industry.

Health Care · Californië$929K Post Ipo Debt
BioSerenity
November 2023

BioSerenity provides remote monitoring and diagnostic software for healthcare sectors.

Health Care · Paris$25.7M Series Unknown
Shorla Pharma
October 2023

Shorla Pharma is an Irish specialty pharmaceutical company.

Biotechnology · Clonmel$35.0M Series B
Corteria Pharmaceuticals
September 2023

Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations.

Biotechnology · Paris$69.5M Series A
Axithra
September 2023

Axithra provides therapeutic medication monitoring and measures beta-lactam antibiotic concentrations in blood.

Biotechnology · Genk$10.7M Seed

Where Kurma Partners invests

Health Care16
Biotechnology14
Medical8
Pharmaceutical8
Therapeutics5
Life Science4

About Kurma Partners's portfolio

How many companies has Kurma Partners invested in?

Kurma Partners has invested in 84 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Kurma Partners invest in?

Kurma Partners's top investment sectors include Health Care, Biotechnology, Medical, Pharmaceutical, Therapeutics. The firm invests across 25 different industry categories.

What is Kurma Partners's largest investment?

Among tracked funding rounds, PanTera received $110.3M in a Series A round. Kurma Partners's total known invested capital is $1.8B.

What is the average investment size for Kurma Partners?

Kurma Partners's average investment size is $26.0M across its portfolio of 84 companies.

What are Kurma Partners's most recent investments?

Recent Kurma Partners portfolio additions include Nuclidium, Minoryx Therapeutics, EvlaBio, Elkedonia, Nuevocor. These companies were founded in 2020 or later.

Reach the founders behind these 84 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →